Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mb1707
- Development stage
- Unknown
- Lead developer
- Mainline Biosciences
- Modality
- Nucleic Acid-Directed Small Molecules → Small Molecules, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Covalent Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Intravenous
01
Overview
MB1707 is a peptide-drug conjugate (PDC) consisting of the chemotherapeutic agent paclitaxel covalently linked to a peptide antagonist of CXC chemokine receptor 4 (CXCR4). It is designed as a targeted therapy for cancer by specifically binding to CXCR4, which is overexpressed on many tumor cells. By blocking the stromal cell-derived factor 1 (SDF-1/CXCL12)/CXCR4 signaling pathway, MB1707 inhibits tumor growth and metastasis. The conjugation with paclitaxel allows for targeted delivery of cytotoxic payload directly to cancer cells expressing high levels of CXCR4[1][2][3][4][5].
- Other names
- paclitaxel-conjugated CXCR4 peptide antagonist MB1707
02
Targets
CXCR4 (C-X-C motif chemokine receptor 4)
Beyond the preview
Go deeper on mb1707.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mb1707.